Clinical efficacy of collagen ⅩⅦ in the treatment of androgenic alopecia
Objective:To evaluate the effectiveness of collagen ⅩⅦ(COL17)and 2 940 fractional lasers in androgenic alopecia treatment.Methods:Between March 2023 and December 2023,100 androgenic alopecia patients who received treatment were selected as research subjects.The experimental group was treated with recombinant humanized COL17 injection;the positive control group was treated with the 2 940 nm dot matrix laser;the negative control group was treated with normal saline injection.All three groups were treated once a month for three months.The average terminal hair density,hair folli-cle width,and other indicators of each group of patients before and after treatment were recorded to compare the differences in efficacy.Results:Before treatment,all indicators of the three groups of pa-tients showed no statistically significant difference(P>0.05).Three months after treatment,the ter-minal hair density significantly increased in both the experimental and positive control groups,and the density in the experimental group was higher than that in the positive control group(P<0.05).The hair follicle width in the experimental group was lower than that in the positive control group,and the hair follicle width in the positive control group was lower than that in the negative control group(P<0.05).The dermal thickness decreased(P<0.05),and the reduction in dermal thickness was greater in the experimental group than in the positive control group(P<0.05).The hair follicle spacing de-creased in both the experimental and positive control groups(P<0.05).Conclusion:The use of COL17 injection can significantly improve the symptoms of androgenic alopecia and promote hair growth.
NETL
NSTL
万方数据
